Mandate

Vinge advises Nuevolution in connection with its listing on Nasdaq Stockholm

Vinge advises Nuevolution AB (publ) in connection with its list change from Nasdaq First North Premier to Nasdaq Stockholm’s main market.

The prospectus was published on 20 June 2018 and the trading on Nasdaq Stockholm commenced on 25 June 2018.
 
Nuevolution AB (publ) is a small molecule drug discovery biotech company. The company was founded in 2001 and is headquartered in Copenhagen, Denmark. 
 
Vinge’s team has primarily consisted of Dain Hård Nevonen, David Andersson, Maria Schultzberg, Nils Fredrik Dehlin, Malte Hedlund, Anna Thoms, Klara Secher and Victor Ericsson.

Related

Vinge advises on the sale of RK Projektledning to Qflow

Vinge has advised the sellers in connection with the sale of all shares in RK Projektledning AB to Qflow Group.
December 05, 2025

Vinge represents IKEA Forestry Investment AB in connection with the acquisition of forest land in Latvia and Lithuania

Vinge assists IKEA Forestry Investment AB (a company within the Inter IKEA group) in the acquisition of a Latvian and a Lithuanian company from Dasos Timberland Fund II (a fund managed by CapMan Natural Capital).
December 05, 2025

Vinge advises and Valcon in connection with the acquisition of Bricobomba

Bricobomba AB is a Swedish company with expertise in data and AI. The acquisition will strengthen Valcon’s capacity in the Nordic region and further expand the company’s ability to deliver comprehensive data and AI-based services to its customers on a pan-European scale.
December 05, 2025